Literature DB >> 25088761

Preventing metachronous gastric lesions after endoscopic submucosal dissection through Helicobacter pylori eradication.

Sungmo Jung1, Chan Hyuk Park, Eun Hye Kim, Su Ji Shin, Hyunsoo Chung, Hyuk Lee, Jun Chul Park, Sung Kwan Shin, Yong Chan Lee, Sang Kil Lee.   

Abstract

BACKGROUND AND AIM: Metachronous recurrence often occurs after endoscopic submucosal dissection for early gastric cancer, and a method for preventing recurrence is unknown. We aimed to identify risk factors for metachronous lesions, and the effects of aspirin use and Helicobacter pylori eradication on preventing recurrence.
METHODS: A total of 1041 consecutive patients who underwent endoscopic submucosal dissection for early gastric cancer between January 2007 and December 2011 were retrospectively analyzed. Every patient was examined endoscopically at 2, 6, and 12 months after endoscopic submucosal dissection, and then annually. Patients were classified into the metachronous group or non-metachronous group according to the existence of metachronous lesions and subdivided by Helicobacter pylori status into three groups: not infected, eradicated after infection, and not eradicated.
RESULTS: At 39 months' median follow-up, metachronous gastric lesions had developed in 35 patients (3.4%), including 16 with dysplasia and 19 cancers. Metachronous group were significantly older than non-metachronous group (P = 0.02). Although non-metachronous group took aspirin more frequently than metachronous group (15.5% vs 5.7%), the difference was statistically insignificant (P = 0.11). In the not eradicated group, the odds ratio of metachronous lesion was 7.762 compared with the not infected group (95% confidence interval, 1.483-60.854; P = 0.02). In the eradicated group, the odd ratio of metachronous lesion was 8.120 compared with not infected group (95% confidence interval, 1.950-58.985; P = 0.01).
CONCLUSION: Helicobacter pylori infection was an independent risk factor for metachronous gastric lesions. However, eradication of Helicobacter pylori alone does not prevent all metachronous lesions in an inflamed stomach.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  HP; Helicobacter pylori; aspirin; eradication; metachronous gastric carcinoma

Mesh:

Year:  2015        PMID: 25088761     DOI: 10.1111/jgh.12687

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  14 in total

1.  Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis.

Authors:  Mitsushige Sugimoto; Masaki Murata; Yoshio Yamaoka
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

2.  Association between macrocytosis and metachronous squamous cell carcinoma of the esophagus after endoscopic resection in men with early esophageal squamous cell carcinoma.

Authors:  Chikatoshi Katada; Tetsuji Yokoyama; Tomonori Yano; Ichiro Oda; Yuichi Shimizu; Hisashi Doyama; Tomoyuki Koike; Kohei Takizawa; Motohiro Hirao; Hiroyuki Okada; Takako Yoshii; Yutaro Kubota; Takenori Yamanouchi; Takashi Tsuda; Tai Omori; Nozomu Kobayashi; Haruhisa Suzuki; Satoshi Tanabe; Keisuke Hori; Norisuke Nakayama; Hirofumi Kawakubo; Naomi Kakushima; Yasumasa Matsuo; Hideki Ishikawa; Akira Yokoyama; Manabu Muto
Journal:  Esophagus       Date:  2019-07-08       Impact factor: 4.230

3.  Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer: a systematic review and meta-analysis.

Authors:  Shiyu Xiao; Sizhu Li; Liya Zhou; Wenjun Jiang; Jinzhe Liu
Journal:  J Gastroenterol       Date:  2018-09-24       Impact factor: 7.527

Review 4.  Endoscopic surveillance of gastric cancers after Helicobacter pylori eradication.

Authors:  Masaaki Kobayashi; Yuichi Sato; Shuji Terai
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

5.  The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis.

Authors:  Pengfei Kong; Ruiyan Wu; Xuechao Liu; Jianjun Liu; Shangxiang Chen; Minting Ye; Chenlu Yang; Ze Song; Wenzhuo He; Chenxi Yin; Qiong Yang; Chang Jiang; Fangxin Liao; Roujun Peng; Zhiwei Zhou; Dazhi Xu; Liangping Xia
Journal:  J Cancer       Date:  2016-11-09       Impact factor: 4.207

6.  Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer.

Authors:  Yuki Michigami; Jiro Watari; Chiyomi Ito; Ken Hara; Takahisa Yamasaki; Takashi Kondo; Tomoaki Kono; Katsuyuki Tozawa; Toshihiko Tomita; Tadayuki Oshima; Hirokazu Fukui; Takeshi Morimoto; Kiron M Das; Hiroto Miwa
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

Review 7.  Characteristics and predictors of gastric cancer after Helicobacter pylori eradication.

Authors:  Satoki Shichijo; Yoshihiro Hirata
Journal:  World J Gastroenterol       Date:  2018-05-28       Impact factor: 5.742

8.  Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial.

Authors:  Maki Kawanaka; Jiro Watari; Noriko Kamiya; Takahisa Yamasaki; Takashi Kondo; Fumihiko Toyoshima; Hisatomo Ikehara; Toshihiko Tomita; Tadayuki Oshima; Hirokazu Fukui; Takashi Daimon; Kiron M Das; Hiroto Miwa
Journal:  Br J Cancer       Date:  2015-12-15       Impact factor: 7.640

9.  Long-Term Effects of Helicobacter pylori Eradication on Metachronous Gastric Cancer Development.

Authors:  Seung Jun Han; Sang Gyun Kim; Joo Hyun Lim; Ji Min Choi; Sooyeon Oh; Jae Yong Park; Jung Kim; Joo Sung Kim; Hyun Chae Jung
Journal:  Gut Liver       Date:  2018-03-15       Impact factor: 4.519

10.  Exploring the Link between Helicobacter pylori Eradication and Metachronous Gastric Cancer Development.

Authors:  Hyo-Joon Yang
Journal:  Gut Liver       Date:  2018-03-15       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.